Yüksel Bora, Uzunel Umut Duygu, Kerci Süleyman Gökhan, Sağban Levent, Küsbeci Tuncay, Örsel Tümay
a Izmir Bozyaka Training and Research Hospital , Department of Ophthalmology , Izmir , Turkey.
Ocul Immunol Inflamm. 2017 Aug;25(4):513-519. doi: 10.3109/09273948.2016.1147587. Epub 2016 Mar 25.
To compare the efficacy and safety of subtenon triamcinolone acetonide (TA) injection with topical nepafenac 0.1% for the treatment of pseudophakic cystoid macular edema (CME).
In this prospective study, the TA group comprised 24 eyes and the nepafenac group 24 eyes. Best-corrected visual acuity (BCVA), central retinal thickness (CRT), intraocular pressure measurements, and slit-lamp fundoscopy were performed in all subjects at baseline, 1, 2, 3, and 6 months.
Changes in BCVA and CRT over four follow-up visits were statistically significant (p<0.001). The mean CRT decreased from 513.3 to 318.9 μm in the TA group and from 483.7 to 278.0 μm in the nepafenac group. This reduction was statistically significant (p<0.001 for both groups).
Our visual and OCT results suggest that both treatment modalities are effective with few side-effects. However, nepafenac is more efficacious than subtenon TA in terms of visual gain and its correlation with the reduction in CRT.
比较球后注射曲安奈德（TA）与局部使用0.1%奈帕芬酸治疗人工晶状体眼黄斑囊样水肿（CME）的疗效和安全性。
在这项前瞻性研究中，TA组有24只眼，奈帕芬酸组有24只眼。在基线、1、2、3和6个月时对所有受试者进行最佳矫正视力（BCVA）、视网膜中央厚度（CRT）测量、眼压测量和裂隙灯眼底检查。
在四次随访中，BCVA和CRT的变化具有统计学意义（p<0.001）。TA组的平均CRT从513.3μm降至318.9μm，奈帕芬酸组从483.7μm降至278.0μm。这种降低具有统计学意义（两组均p<0.001）。
我们的视力和光学相干断层扫描结果表明，两种治疗方式均有效且副作用少。然而，就视力提高及其与CRT降低的相关性而言，奈帕芬酸比球后TA更有效。
